Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 3.83 -0.04 (1.03%)
Day High: 4.01
Day Low:  3.79
Volume:    416,499
4:00 PM ET
Sep 23, 2016

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations

Aug 24, 2016 / 3:30 PM CT
Aug 16, 2016 / 9:10 AM ET